I. Braunschweig

P. Bierman, I. Flinn, C. Flowers, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ethnic disparities in survival of adult B-cell acute lymphoblastic leukemia in modern era – a SEER analysis

A. Verma, I. Braunschweig, A. Shastri, 2020, Leukemia & lymphoma.

Outcomes of Autologous Hematopoietic Cell Transplantation Compared With Chemotherapy Consolidation Alone for Non-High-Risk Acute Myeloid Leukemia in First Complete Remission in a Minority-Rich Inner-City Cohort With Limited Access to Allografts.

A. Verma, I. Braunschweig, A. Shastri, 2019, Clinical lymphoma, myeloma & leukemia.

Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1.

N. Ueno, K. Cleary, K. van Besien, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease

A. Verma, I. Braunschweig, C. Minniti, 2018, Leukemia & lymphoma.

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

A. Verma, U. Steidl, I. Braunschweig, 2021, Experimental Hematology & Oncology.

Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor

K. Pradhan, A. Verma, I. Braunschweig, 2016, Leukemia & lymphoma.

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation.

K. Cleary, K. van Besien, I. Braunschweig, 2001, Blood.

A Case Series of MGUS and COVID-19.

A. Verma, S. Goel, I. Braunschweig, 2020, British journal of haematology.

Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus

I. Braunschweig, S. Vadhan-Raj, D. Przepiorka, 2001, Bone Marrow Transplantation.

Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.

N. Ueno, K. Cleary, K. van Besien, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Eosinophilic Variant of Chronic Myeloid Leukemia with Vascular Complications

I. Braunschweig, A. Chadburn, V. Gotlib, 2003, Leukemia & lymphoma.

Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data.

A. Verma, S. Goel, I. Braunschweig, 2020, Clinical lymphoma, myeloma & leukemia.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

I. Flinn, D. Miklos, C. Jacobson, 2019, The Lancet. Oncology.

Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia

E. Estey, M. Andreeff, N. Ueno, 2001, American journal of hematology.

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.

P. Thall, M. Andreeff, N. Ueno, 2001, Blood.

AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1

D. Miklos, C. Jacobson, N. Bartlett, 2017 .

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis

A. Verma, I. Braunschweig, K. Gritsman, 2020, Journal of hematology & oncology.

Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy.

P. Mclaughlin, F. Cabanillas, J. Cox, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary C utaneous N on-Hodgkin's L ymphoma o f A nn A rbor Stage I : P referential C utaneous R elapses b ut H igh C ure Rate W ith D oxorubicin-Base d T herapy

P. Mclaughlin, J. Cox, F. Cabanillas, 2001 .

Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis

K. Pradhan, A. Verma, R. Snyder, 2019, Leukemia.

North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.

K. Pradhan, S. Ogawa, A. Graber, 2018, Blood.

Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone

A. Verma, U. Steidl, M. Roth, 2014, Leukemia & lymphoma.

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.

Amit Verma, Adrian Wiestner, Samir Parekh, 2010, Blood.

Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.

N. Ueno, K. Cleary, B. Andersson, 1999, Blood.

High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer.

A. Gee, I. Braunschweig, J. Gajewski, 2000, Cytotherapy.

Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation

K. Cleary, R. Champlin, I. Braunschweig, 1999, Bone Marrow Transplantation.

Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

G. Papanicolaou, J. Mehta, J. Panse, 2018, The Lancet.

Ibrutinib‐induced severe liver injury

I. Braunschweig, M. Janakiram, O. Derman, 2017, Clinical case reports.

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

J. Friedberg, I. Flinn, D. Miklos, 2016 .

Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

D. Miklos, E. Jacobsen, C. Jacobson, 2018 .

Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

I. Flinn, D. Miklos, C. Jacobson, 2020 .

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.

D. Miklos, C. Jacobson, N. Bartlett, 2020, Blood.

Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population

K. Pradhan, Amit Verma, I. Braunschweig, 2021, Bone Marrow Transplantation.

Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

D. Miklos, E. Jacobsen, C. Jacobson, 2018 .

Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting.

K. Pradhan, Amit Verma, U. Steidl, 2021, Stem cell investigation.

Pharmacokinetics‐directed Intravenous Busulfan Combined With High‐dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma

A. Verma, I. Braunschweig, S. Barta, 2017, Clinical lymphoma, myeloma & leukemia.

Barriers to Allogeneic Hematopoietic Stem Cell Transplantation for Human T Cell Lymphotropic Virus 1-Associated Adult T Cell Lymphoma-Leukemia in the United States: Experience from a Large Cohort in a Major Tertiary Center.

A. Verma, I. Braunschweig, U. Shah, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Epidemiology and survival trend of adult T‐cell leukemia/lymphoma in the United States

K. Pradhan, A. Verma, I. Braunschweig, 2019, Cancer.

Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy

A. Verma, I. Braunschweig, D. Narasimhulu, 2016, Oncotarget.

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

D. Miklos, C. Gisselbrecht, C. Jacobson, 2019, Blood.

High prevalence of pulmonary findings in computed tomographies of HTLV-1-infected patients with and without adult-T cell leukemia/lymphoma – implications for staging

A. Verma, I. Braunschweig, B. Zalta, 2019, Leukemia & lymphoma.

JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?

A. Verma, I. Braunschweig, M. Janakiram, 2016, Biomarker Research.

Urinary retention in infants: unusual presentation of pelvic tumors.

I. Braunschweig, S. Schultz, 1994, New Jersey medicine : the journal of the Medical Society of New Jersey.